Cargando…

Machine‐learning–based early prediction of end‐stage renal disease in patients with diabetic kidney disease using clinical trials data

AIM: To predict end‐stage renal disease (ESRD) in patients with type 2 diabetes by using machine‐learning models with multiple baseline demographic and clinical characteristics. MATERIALS AND METHODS: In total, 11 789 patients with type 2 diabetes and nephropathy from three clinical trials, RENAAL (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belur Nagaraj, Sunil, Pena, Michelle J., Ju, Wenjun, Heerspink, Hiddo L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756814/ https://www.ncbi.nlm.nih.gov/pubmed/32844582 http://dx.doi.org/10.1111/dom.14178

Ejemplares similares

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease
por: Pena, Michelle J., et al.
Publicado: (2016)

Machine learning algorithm for early detection of end-stage renal disease
por: Segal, Zvi, et al.
Publicado: (2020)

Machine learning to predict end stage kidney disease in chronic kidney disease
por: Bai, Qiong, et al.
Publicado: (2022)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?
por: Perco, Paul, et al.
Publicado: (2018)

Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?
por: Chung, Edmund Y. M., et al.
Publicado: (2022)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Identifying patients at increased risk of hypoglycaemia in primary care: Development of a machine learning‐based screening tool
por: Crutzen, Stijn, et al.
Publicado: (2021)

Machine Learning Improves Upon Clinicians' Prediction of End Stage Kidney Disease
por: Chuah, Aaron, et al.
Publicado: (2022)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care
por: Provenzano, Michele, et al.
Publicado: (2018)

A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes
por: Mulder, Skander, et al.
Publicado: (2020)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2021)

Erratum to: Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2022)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

End Stage and Chronic Kidney Disease: Associations with Renal Cancer
por: Russo, Paul
Publicado: (2012)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death
por: Dalrymple, Lorien S., et al.
Publicado: (2010)

Preoperative Evaluation in Patients With End-Stage Renal Disease and Chronic Kidney Disease
por: Nasr, Rabih, et al.
Publicado: (2017)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Successful Kidney Transplantation for End-Stage Renal Disease in Marfan's Syndrome
por: Ryosaka, Makoto, et al.
Publicado: (2013)

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders
por: Schievink, Bauke, et al.
Publicado: (2014)

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations
por: Mol, Peter G. M., et al.
Publicado: (2018)

Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases
por: Damron, Kelli Collins, et al.
Publicado: (2022)

Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease
por: Zou, Yutong, et al.
Publicado: (2022)

Association of Constipation with risk of end-stage renal disease in patients with chronic kidney disease
por: Lu, Chung-Yen, et al.
Publicado: (2019)

Comparison of the Quality of Sleep in Patients With Chronic Kidney Disease and End-Stage Renal Disease
por: Mujahid, Mehreen, et al.
Publicado: (2022)

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
por: Smeijer, J. David, et al.
Publicado: (2023)

IgG4-Related Kidney Disease Associated With End-Stage Kidney Disease, Renal Pseudotumor, and Renal Vein Thrombosis
por: Tawhari, Mohammed, et al.
Publicado: (2022)

Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease
por: Mathew, Roy O, et al.
Publicado: (2016)

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
por: Kreiner, Frederik F., et al.
Publicado: (2023)

End Stage Renal Disease and Medicare
por: Greer, Joel W.
Publicado: (2003)

End of Life Care in End-Stage Kidney Disease
por: Prabhu, Ravindra Attur, et al.
Publicado: (2021)

Early goal-directed therapy in patients with end-stage renal disease
por: Donnino, M, et al.
Publicado: (2004)

Early-Onset Type 2 Diabetes as a Risk Factor for End-Stage Renal Disease in Patients With Diabetic Kidney Disease
por: Zheng, Li, et al.
Publicado: (2020)

A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: Need for new reference ranges
por: Ray, Lopamudra, et al.
Publicado: (2015)

Automated Peritoneal Dialysis is Suitable for Polycystic Kidney Disease Patients with End-Stage Renal Disease
por: Li, Xiao, et al.
Publicado: (2015)

Uremic and Post-Transplant Gastropathy in Patients With Chronic Kidney Disease and End-Stage Renal Disease
por: Turshudzhyan, Alla, et al.
Publicado: (2020)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_69mrfk9hf586m5fe2iu76sekjp